Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379938 · ClinicalTrials.gov registry record · Phase 1
B-19 Parvovirus Vaccine Study
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT00379938 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 43 participants.
The verdict
NCT00379938, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study investigates the safety and effectiveness of a preventative vaccine for parvovirus B-19 infection. Eighty-nine healthy adults ages 18-49, whose blood tests negative for B-19, will be enrolled. Participants will be randomly chosen to receive 1 of 4 possible vaccine types: low dose of the vaccine and an adjuvant (substance which assists with transfer of medication to body); high dose of the vaccine alone; high dose of the vaccine and an adjuvant; or saline (substance containing no medication). Participants will receive 3 vaccinations over a 6 month period and will be followed for 6 additional months. Blood samples will be taken at months 1, 2, 6, 7 and 12 to determine if antibody, protein produced by the body's immune system that recognizes and helps fight infections, has been formed to the vaccine. These tests measure vaccine efficacy, i.e., determine if the vaccine induces immunity. All participants will be followed closely for safety throughout the study.
Interventions
- DRUG Placebo
- BIOLOGICAL MF-59
- BIOLOGICAL VAI-VP705 (parvovirus B-19 vaccine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00379938
The ClinicalTrials.gov registry entry for NCT00379938 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00379938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00379938 about?
NCT00379938 is a clinical study titled "B-19 Parvovirus Vaccine Study". This study investigates the safety and effectiveness of a preventative vaccine for parvovirus B-19 infection. Eighty-nine healthy adults ages 18-49, whose blood tests negative for B-19, will be enrolled. Participants will be randomly chosen to receive 1 of 4 possible vaccine types: low dose of the v...
What is the current status of trial NCT00379938?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2006-08. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00379938?
The interventions under investigation include: Placebo (DRUG), MF-59 (BIOLOGICAL), VAI-VP705 (parvovirus B-19 vaccine) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00379938?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.